X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA SUN PHARMA ALEMBIC PHARMA/
SUN PHARMA
 
P/E (TTM) x 29.0 25.6 113.1% View Chart
P/BV x 6.6 3.7 176.7% View Chart
Dividend Yield % 0.7 0.6 116.0%  

Financials

 ALEMBIC PHARMA   SUN PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
SUN PHARMA
Mar-17
ALEMBIC PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs792842 94.0%   
Low Rs443572 77.4%   
Sales per share (Unadj.) Rs167.0131.6 126.9%  
Earnings per share (Unadj.) Rs38.232.7 116.7%  
Cash flow per share (Unadj.) Rs42.038.0 110.6%  
Dividends per share (Unadj.) Rs4.003.50 114.3%  
Dividend yield (eoy) %0.60.5 130.9%  
Book value per share (Unadj.) Rs84.9152.7 55.6%  
Shares outstanding (eoy) m188.522,399.26 7.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.75.4 68.8%   
Avg P/E ratio x16.221.6 74.8%  
P/CF ratio (eoy) x14.718.6 78.9%  
Price / Book Value ratio x7.34.6 157.0%  
Dividend payout %10.510.7 97.9%   
Avg Mkt Cap Rs m116,3831,696,877 6.9%   
No. of employees `000NA17.5 0.0%   
Total wages/salary Rs m4,21449,023 8.6%   
Avg. sales/employee Rs ThNM18,028.3-  
Avg. wages/employee Rs ThNM2,798.8-  
Avg. net profit/employee Rs ThNM4,479.5-  
INCOME DATA
Net Sales Rs m31,487315,784 10.0%  
Other income Rs m556,232 0.9%   
Total revenues Rs m31,542322,016 9.8%   
Gross profit Rs m10,060100,893 10.0%  
Depreciation Rs m72212,648 5.7%   
Interest Rs m373,998 0.9%   
Profit before tax Rs m9,35690,479 10.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m-299 -1.5%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,16012,116 17.8%   
Profit after tax Rs m7,19478,462 9.2%  
Gross profit margin %31.931.9 100.0%  
Effective tax rate %23.113.4 172.4%   
Net profit margin %22.824.8 92.0%  
BALANCE SHEET DATA
Current assets Rs m15,066329,537 4.6%   
Current liabilities Rs m7,674178,870 4.3%   
Net working cap to sales %23.547.7 49.2%  
Current ratio x2.01.8 106.6%  
Inventory Days Days6779 84.8%  
Debtors Days Days4183 48.8%  
Net fixed assets Rs m8,237204,766 4.0%   
Share capital Rs m3772,399 15.7%   
"Free" reserves Rs m15,416363,997 4.2%   
Net worth Rs m16,005366,397 4.4%   
Long term debt Rs m014,361 0.0%   
Total assets Rs m24,594614,102 4.0%  
Interest coverage x255.223.6 1,080.1%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.30.5 249.0%   
Return on assets %29.413.4 219.0%  
Return on equity %44.921.4 209.9%  
Return on capital %58.724.8 236.2%  
Exports to sales %55.70-   
Imports to sales %10.40-   
Exports (fob) Rs m17,551NA-   
Imports (cif) Rs m3,283NA-   
Fx inflow Rs m17,81144,118 40.4%   
Fx outflow Rs m5,31824,484 21.7%   
Net fx Rs m12,49319,634 63.6%   
CASH FLOW
From Operations Rs m9,30470,822 13.1%  
From Investments Rs m-3,105-42,216 7.4%  
From Financial Activity Rs m-1,959-22,854 8.6%  
Net Cashflow Rs m4,2406,107 69.4%  

Share Holding

Indian Promoters % 74.1 63.7 116.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 5.1 56.5%  
FIIs % 9.1 23.0 39.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 8.3 167.5%  
Shareholders   49,328 133,026 37.1%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  STRIDES SHASUN LTD  FDC LTD.  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - ALEMBIC LTD COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS